Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has submitted a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from Integrated Registry Management Services Private Limited, the Registrar and Transfer Agent of the Company, for the quarter and half year ended September 30, 2026.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the closure of its trading window from October 1, 2026, due to the finalization of unaudited financial results for the quarter and half year ending September 30, 2026.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the voting results and scrutinizer report for its 35th Annual General Meeting (AGM) held on September 25, 2026. The meeting was conducted through video conferencing without the physical presence of members, and the voting facility was provided by National Securities Depository Limited (NSDL). The report confirms that the meeting was conducted with the requisite quorum and that the management ensured compliance with relevant regulations.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd held its 35th Annual General Meeting on September 25, 2026, through Video Conferencing/Other Audio Visual Means. The meeting approved the appointment of new directors and reappointment of the Managing Director. The Company Secretary read out the list of Ordinary and Special Resolutions, and the Statutory Audit Report and Secretarial Audit Report were free from qualifications.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd issued a clarification regarding a significant increase in trading volume of its equity shares across exchanges, stating that the company has made all requisite disclosures and the increase is purely market-driven.

Caplin Point Laboratories Ltd

The BSE has sought clarification from Caplin Point Laboratories Ltd regarding a movement in volume on September 25, 2026, and is awaiting a response.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has published a newspaper advertisement for the notice of its 35th Annual General Meeting to be held on September 25, 2026, through Video Conferencing/Other Audio-Visual Means, along with e-voting information.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has dispatched the 35th AGM Notice and Annual Report for the Financial Year 2025-26 to shareholders. The AGM will be held on September 22, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM. Shareholders are requested to update their email addresses with the Company / Depository / STA to ensure receipt of any communication from the Company / STA from time to time.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has submitted its Business Responsibility and Sustainability Report for the Financial Year 2025-26, as per Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the notice of its 35th Annual General Meeting (AGM) to be held on September 25, 2026, through video conferencing. The AGM will consider the adoption of financial statements, declaration of final dividend, and re-appointment of Dr. Sridhar Ganesan as Managing Director.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its Annual Report for the Financial Year 2025-26, showcasing a 12.89% growth in revenue and 20.08% growth in net profit. The company has demonstrated a decade-long pattern of compounding profits without debt funding, with free cash reserves growing 21X over the past decade.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has published a newspaper advertisement for its 35th Annual General Meeting (AGM) to be held on September 25, 2026, through video conferencing.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd's subsidiary, Caplin One Labs Limited, has received a Good Manufacturing Practices (GMP) Compliance Certificate from INVIMA, the regulatory authority in Colombia, for its manufacturing unit. The certificate confirms compliance with GMP requirements for the manufacture of oncology drug products.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd informed about the completion of an unannounced US FDA inspection at its subsidiary Caplin Steriles Limited's manufacturing facility. The inspection was conducted between August 13, 2026, and August 21, 2026, and resulted in 10 observations, all of which are procedural in nature.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has released the transcript of its earnings call for Q1 FY 2026-27, which is available on its website. The company's financial performance for the quarter ended June 30, 2026, is discussed in the call.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has made available the audio recording of its Q1 FY 2026-27 earnings call on its website.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 202.95 crores and net profit for the period at Rs. 120.38 crores. The company has also recommended a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026. Additionally, the board has approved the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director and Chief Financial Officer.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the appointment of directors, including the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director and Chief Financial Officer.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 120.38 crores. The company has also recommended a final dividend of Rs. 4 per equity share and approved the re-appointment of its Managing Director and the appointment of a new Whole-Time Director.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the record date for its final dividend as September 18, 2026, ahead of its 35th Annual General Meeting on September 25, 2026.